Management of Nanostim leadless pacemaker early-life battery failures. A single center experience

Abstract

\n \n \n Type of funding sources: None.\n Background/introduction Early studies of the Nanostim leadless pacemaker demonstrated technical feasibility effective pacing performance at the short-term. However, recently the Nanostim proved to be susceptible to early-life battery failures.\n Purpose In this study, we addressed the following research questions:\n 1) What percentage of Nanostim LPs experience early-life battery failure?\n 2) Is Nanostim extraction and subsequent pacemaker reimplantation safe and effective?\n 3) Is three monthly follow-up under the Nanostim advisory effective at preventing Nanostim LP related in-between hospitalizations?\n Methods In a retrospective study, we collected data of 49 Nanostim implanted patients with a mean follow up of 3 (±1.5) years at our tertiary hospital.\n Results Nanostim early-life battery failure in our population was 37% (18/49). Extraction of 14 Nanostim pacemakers (device age 1040\xa0 ± 467 days) in an older population (80 ± 7 years) was safe (0 complications) and effective (80% extraction success, 100% reimplantation success). All known cases of early-life battery failure were identified during the three monthly follow-up consultations.\n Conclusions Nanostim LP early-life battery failure is substantially higher than previously reported.\n In case of dysfunction Nanostim extraction in an older population is safe and effective. Three monthly follow-up is effective at preventing in-between Nanostim related hospitalization. Abstract Figure. Management of Nanostim battery failure\n